Pulmonary alveolar proteinosis (PAP) is an ultra-rare lung disease with approximately 3,600 diagnosed cases in the United States. Unfortunately, some people are potentially living with the disease ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has unveiled the Savara Early Access Program, a significant initiative aimed at ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the appointment of Braden Parker as Chief Commercial Officer, ...

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Savara (SVRA – Research Report) today and set a price target of $10.00.

Molgramostim is in phase 3 clinical trials to treat autoimmune pulmonary alveolar proteinosis, or aPAP. Molgramostim has received an FDA orphan drug designation — given to drugs targeting rare ...

A 40-year-old man presented to the emergency department with a 5-day history of fevers, sore throat, fatigue, subjective ...

Healthcare professionals and autoimmune Pulmonary Alveolar Proteinosis (aPAP) patients who are interested to learn more about Savara's EAP for molgramostim, including eligibility criteria ...

APAP is a rare autoimmune condition that falls under the broader category of Pulmonary Alveolar Proteinosis (PAP). The body's immune system accidentally produces antibodies against granulocyte ...

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), retaining the price target of ...

Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was ...

Subtle lesions of Langerhans' cell histiocytosis, lymphangioleiomyomatosis, or alveolar proteinosis can be overlooked. In some cases, even in surgical lung biopsies, the lesion may be completely ...

Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant ...